Literature DB >> 7198726

Specific estradiol binding in schwannomas, meningiomas, and neurofibromas.

R L Martuza, D T MacLaughlin, R G Ojemann.   

Abstract

The cytoplasmic fractions of schwannomas (acoustic neuromas), meningiomas, and neurofibromas were assayed for the presence of estrogen receptors. Specific estradiol binding was detected in 7 of 16 schwannomas, 7 of 10 meningiomas, and 1 of 6 neurofibromas. A nontumorous vestibular nerve was also studied and showed no estradiol binding. In the tumors, the concentration of the estradiol binding sites as estimated by saturation binding analysis covered a wide range of values (21 to 2430 fmol/g of tumor) but, overall, meningiomas contained the highest amount of estradiol binder. A Scatchard plot analysis of one of the schwannoma specimens demonstrated high affinity estradiol binding (Ka = 1.695 X 10(10) M-1). Although there were more females than males in each tumor category, the overall incidence of estradiol binding was similar in males (5 of 11, 45%) and in females (10 of 21, 48%). In 5 cases, progestin binding was also measured and was detected in two meningiomas (both from female patients); one meningioma and two neurofibromas showed no progestin binding. A discussion is presented of the possible role of estradiol in the pathogenesis or modulation of meningeal and Schwann cell tumors as well as in the genetic disorder neurofibromatosis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7198726     DOI: 10.1227/00006123-198112000-00009

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  18 in total

1.  Estrogen receptor expression in sporadic vestibular schwannomas.

Authors:  Carrie M Brown; Zana K Ahmad; Allen F Ryan; Joni K Doherty
Journal:  Otol Neurotol       Date:  2011-01       Impact factor: 2.311

2.  Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.

Authors:  Andrew K Patel; Thomas H Alexander; Ali Andalibi; Allen F Ryan; Joni K Doherty
Journal:  Laryngoscope       Date:  2008-08       Impact factor: 3.325

3.  Incidence of vestibular schwannomas in the United States.

Authors:  Varun R Kshettry; Jason K Hsieh; Quinn T Ostrom; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2015-05-30       Impact factor: 4.130

4.  Identification of growth hormone receptor in localised neurofibromas of patients with neurofibromatosis type 1.

Authors:  K S G Cunha; E P Barboza; E C Da Fonseca
Journal:  J Clin Pathol       Date:  2003-10       Impact factor: 3.411

5.  Small heat-shock protein is expressed in meningiomas and in granulofilamentous inclusion bodies.

Authors:  N Yokoyama; T Iwaki; J E Goldman; J Tateishi; M Fukui
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

6.  Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470.

Authors:  T Yazaki; Y Takamiya; P C Costello; T Mineta; A G Menon; S D Rabkin; R L Martuza
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

7.  Progestin and oestrogen receptors in meningiomas. Biochemical characterization, clinical and pathological correlations in 42 cases.

Authors:  H Magdelenat; B F Pertuiset; M Poisson; P M Martin; J Philippon; B Pertuiset; A Buge
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

8.  Steroid hormone receptors in human meningiomas, gliomas and brain metastases.

Authors:  M Poisson; B F Pertuiset; J J Hauw; J Philippon; A Buge; M Moguilewsky; D Philibert
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

Review 9.  The biology of meningiomas.

Authors:  I E McCutcheon
Journal:  J Neurooncol       Date:  1996-09       Impact factor: 4.130

10.  Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases.

Authors:  J Jääskeläinen; E Laasonen; J Kärkkäinen; M Haltia; H Troupp
Journal:  Acta Neurochir (Wien)       Date:  1986       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.